BridgeBio Pharma, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| BBIO | ALNY | IONS | BMRN | ROIV | GPCR | |
|---|---|---|---|---|---|---|
| Market cap | 12.85B | 30.38B | 7.26B | 10.72B | 24.99B | 1.71B |
| P/E (TTM) | — | 38.3 | — | 149.7 | — | — |
| Forward P/E | 2,275.1 | 18.3 | -39.3 | 8.3 | -20.1 | -11.3 |
| Price/book | -5.1 | 22.4 | 16.4 | 1.7 | 5.9 | 1.3 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +16.37% | −51.17% | −35.85% | +5.57% | +118.63% | −15.40% |
| Today | +0.61% | −2.43% | −3.56% | +1.09% | −2.40% | −6.38% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All BBIO news ›BridgeBio Pharma reports symptom gains in Phase 3 encaleret trial
The FDA has accepted the ADH1 application for priority review, with a May 8, 2027 target decision date. Symptom improvements were reported by all encaleret recipients versus 46 per cent on standard care as BridgeBio Pharma, Inc. NASDAQBBIO…
BridgeBio Pharma (BBIO) Reports Positive Phase 3 Trial Results for Encaleret in ADH1 Treatment
On October 11, 2026, BridgeBio Pharma Inc (NASDAQ: BBIO) announced encouraging data from its Phase 3 CALIBRATE trial evaluating encaleret for autosomal dominant hypocalcemia type 1 (ADH1). The findings highlight significant clinical…
BridgeBio Pharma (BBIO) Receives a Buy from Barclays
In a report released today, Eliana Merle from Barclays maintained a Buy rating on BridgeBio Pharma, with a price target of $156.00. According to TipRanks, Merle is an analyst with an average return of -1.0% and a 36.72% success rate. Merle…
BridgeBio Pharma price target lowered to $156 from $157 at Barclays
Barclays lowered the firm’s price target on BridgeBio Pharma (BBIO) to $156 from $157 and keeps an Overweight rating on the shares. The firm exp... BridgeBio Pharma price target lowered to $156 from $157 at Barclays Barclays lowered the…
BridgeBio Pharma announces FDA acceptance of oral infigratinib NDA
BridgeBio Pharma (BBIO) announced the FDA has accepted for filing its new drug application, or NDA, with Priority Review for oral infigratinib f... BridgeBio Pharma announces FDA acceptance of oral infigratinib NDA BridgeBio Pharma (BBIO)…
Analysts Conflicted on These Healthcare Names: BridgeBio Pharma (BBIO) and Vaxcyte (PCVX)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on BridgeBio Pharma (BBIO) and Vaxcyte (PCVX). In a report released yesterday, Whitney Ijem from Canaccord Genuity maintained a Buy rating on BridgeBio Pharma,…
BridgeBio reports improved symptoms in Phase 3 trial of rare-disease drug
(BBIO:NASDAQ) Seeking Alpha jittawit.21/iStock via Getty Images BridgeBio Pharma (BBIO) reported positive results from a late-stage clinical trial of its experimental drug encaleret, showing improvements in symptoms and bone health among…
Efzimfotase alfa showed numerical improvement in Six-Minute Walk Test achieving mean difference of 17.05 metres vs placebo in treatment-naïve adolescents and adults…
In the overall population, at week 25, efzimfotase alfa achieved a least squares (LS) mean difference of 17.05 metres (p=0.1675) change from baseline in the primary endpoint of 6MWT, compared to placebo. The lack of statistical…
BridgeBio Pharma, Inc. : Insider Transactions
Follow insider transactions on BridgeBio Pharma, Inc. in real time. Filter by importance or transaction type and analyze the history on MarketScreener. Insider Transactions BridgeBio Pharma, Inc. Latest insider transactions for BridgeBio…
BridgeBio Pharma, Inc.: News in other languages | BBIO | US10806X1028
BridgeBio Pharma, Inc.: News, information and stories for BridgeBio Pharma, Inc. | Nasdaq: BBIO | Nasdaq Other languages BridgeBio Pharma, Inc. All financial news and data tailored to specific country editions
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
marketscreener.com12
-
markets.businessinsider.com5
-
gurufocus.com3
-
tradingview.com3
-
stocktitan.net2
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 31 articles, not a forecast.